Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12137-12149

  Chang, Yu Chao ^a,b   Lin, Cheng Wei ^a   Yu, Cheng Chia ^a,b   Wang, Bing Yen ^a,c,d   Huang, Yu Hao ^a   Hsieh, Yang Chih ^a   Kuo, Yu Liang ^a,b   Chang, Wen Wei ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

EZH2; H3K27me3; Oral submucous fibrosis; Resveratrol; ZEB1

Indexed keywords

MESSENGER RNA; MICRORNA 200C; RESVERATROL; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR ZEB1; EZH2 PROTEIN, HUMAN; STILBENE DERIVATIVE; ZEB1 PROTEIN, HUMAN;

ANTIFIBROSIS ACTIVITY; ARTICLE; BLOOD LEVEL; BUCCAL MUCOSAL FIBROBLAST; CELL ACTIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; EPIGENETICS; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MYOFIBROBLAST; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; FIBROBLAST; GENETICS; METABOLISM; MOUTH DISEASE; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; PRECANCER;

ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENOMICS; FIBROBLASTS; HUMANS; MOUTH MUCOSA; MOUTH NEOPLASMS; MYOFIBROBLASTS; ORAL SUBMUCOUS FIBROSIS; PRECANCEROUS CONDITIONS; STILBENES; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84962834142     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7763     Document Type: Article

References (47)

1. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ and Warnakulasuriya S. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol. 2006; 42:561-568.
2. Avon SL. Oral mucosal lesions associated with use of quid. J Can Dent Assoc. 2004; 70:244-248.
3. Wang YY, Tail YH, Wang WC, Chen CY, Kao YH, Chen YK and Chen CH. Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health. 2014; 14:99.
4. Pindborg JJ and Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966; 22:764-779.
5. Haque MF, Harris M, Meghji S and Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Cytokine. 1998; 10:713-719.
6. van Wyk CW, Seedat HA and Phillips VM. Collagen in submucous fibrosis: an electron-microscopic study. J Oral Pathol Med. 1990; 19:182-187.
7. Chang YC, Yang SF, Tai KW, Chou MY and Hsieh YS. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol. 2002; 38:195-200.
8. Yang SF, Hsieh YS, Tsai CH, Chen YJ and Chang YC. Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis. Oral Dis. 2007; 13:234-238.
9. Haque MF, Meghji S, Khitab U and Harris M. Oral submucous fibrosis patients have altered levels of cytokine production. J Oral Pathol Med. 2000; 29:123-128.
10. Chang YC, Tsai CH, Lai YL, Yu CC, Chi WY, Li JJ and Chang WW. Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1. J Cell Mol Med. 2014; 18:698-708.
11. Novelle MG, Wahl D, Dieguez C, Bernier M and de Cabo R. Resveratrol supplementation: Where are we now and where should we go? Ageing Res Rev. 2015; 21:1-15.
12. Conte E, Fagone E, Fruciano M, Gili E, Iemmolo M and Vancheri C. Anti-inflammatory and antifibrotic effects of resveratrol in the lung. Histol Histopathol. 2015; 30:523-529.
13. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K and Weng X. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014; 63:166-173.
14. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, Bosch J and Garcia-Pagan JC. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2013; 58:904-910.
15. Bai Y, Lu H, Wu C, Liang Y, Wang S, Lin C, Chen B and Xia P. Resveratrol inhibits epithelial-mesenchymal transition and renal fibrosis by antagonizing the hedgehog signaling pathway. Biochem Pharmacol. 2014; 92:484-493.
16. Li J, Qu X, Ricardo SD, Bertram JF and Nikolic-Paterson DJ. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol. 2010; 177:1065-1071.
17. Hu FW, Tsai LL, Yu CH, Chen PN, Chou MY and Yu CC. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res. 2012; 56:1247-1258.
18. Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V and Della Ragione F. Resveratrol: from basic studies to bedside. Cancer Treat Res. 2014; 159:167-184.
19. Hill L, Browne G and Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer. 2013; 132:745-754.
20. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154:61-74.
21. Kramer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P, Gelse K, Beyer C, Distler A, Marquez VE, Distler O, Schett G and Distler JH. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis. 2013; 72:614-620.
22. Ruthenburg AJ, Li H, Patel DJ and Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol. 2007; 8:983-994.
23. Carey MF, Peterson CL and Smale ST. Chromatin Immunoprecipitation (ChIP). Cold Spring Harbor Protocols. 2009; 2009:pdb.prot5279.
24. Feng X, Wang Z, Fillmore R and Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014; 344:166-173.
25. Kalluri R and Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003; 112:1776-1784.
26. Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P and Yang J. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012; 302:F369-379.
27. Xiao Y, Zhou Y, Chen Y, Zhou K, Wen J, Wang Y, Wang J and Cai W. The expression of epithelial-mesenchymal transition-related proteins in biliary epithelial cells is associated with liver fibrosis in biliary atresia. Pediatr Res. 2015; 77:310-315.
28. Yang Z and Wang L. Regulation of microRNA expression and function by nuclear receptor signaling. Cell Biosci. 2011; 1:31.
29. Zhou Y, Lin S, Zhang L and Li Y. Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-alpha pathway. Mol Cell Biochem. 2016; 411:143-150.
30. Yu CC, Tsai CH, Hsu HI and Chang YC. Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral submucous fibrosis. PLoS One. 2013; 8:e55122.
31. Cedar H and Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009; 10:295-304.
32. Bracken AP, Dietrich N, Pasini D, Hansen KH and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006; 20:1123-1136.
33. Singh CK, Liu X and Ahmad N. Resveratrol, in its natural combination in whole grape, for health promotion and disease management. Ann N Y Acad Sci. 2015.
34. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425:191-196.
35. Kuno A, Tanno M and Horio Y. The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy. Ann N Y Acad Sci. 2015.
36. Wei J, Ghosh AK, Chu H, Fang F, Hinchcliff ME, Wang J, Marangoni RG and Varga J. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor beta Signaling. Arthritis Rheumatol. 2015; 67:1323-1334.
37. Tao K, Bai X, Jia W, Liu Y, Zhu X, Han J, Dong M, Li J, Chen D and Hu D. Effects of resveratrol on the treatment of inflammatory response induced by severe burn. Inflammation. 2015; 38:1273-1280.
38. Yang SJ and Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism. 2014; 63:693-701.
39. Yu HP, Hsu JC, Hwang TL, Yen CH and Lau YT. Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock. 2008; 30:324-328.
40. Gupta S, Reddy MV and Harinath BC. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis. Indian J Clin Biochem. 2004; 19:138-141.
41. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, Durazzo M, Cavallo-Perin P and Cassader M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 2013; 20:1323-1331.
42. Li C, Xu X, Wang XJ and Pan Y. Imine resveratrol analogues: molecular design, Nrf2 activation and SAR analysis. PLoS One. 2014; 9:e101455.
43. St John SE, Jensen KC, Kang S, Chen Y, Calamini B, Mesecar AD and Lipton MA. Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2. Bioorg Med Chem. 2013; 21:6022-6037.
44. Ayakannu T, Taylor AH, Willets JM, Brown L, Lambert DG, McDonald J, Davies Q, Moss EL and Konje JC. Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma. Mol Hum Reprod. 2015; 21:723-735.
45. Mohelnikova-Duchonova B, Oliverius M, Honsova E and Soucek P. Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma. Dis Markers. 2012; 32:203-210.
46. McNeill RE, Miller N and Kerin MJ. Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol. 2007; 8:107.
47. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.